Judgment of the General Court in Case T-227/21 | Illumina v Commission
Date of article: 13/07/2022
Daily News of: 13/07/2022
Country: 
EUROPE
Author: Court of Justice of the European Union
Article language: en
Link: https://curia.europa.eu/jcms/upload/docs/application/pdf/2022-07/cp220123en.pdf
PRESS RELEASE No 123/22
Luxembourg, 13 July 2022
Judgment of the General Court in Case T-227/21 | Illumina v Commission
The General Court upholds the decisions of the Commission accepting a referral request from France, as joined by other Member States, asking it to assess the proposed acquisition of Grail by Illumina
The Commission has the competence to examine that concentration which did not have a European dimension or fall within the scope of the national merger control rules of Member States of the European Union or States party to the Agreement on the European Economic Area
Illumina is an American company specialising in genomic sequencing. It develops, manufactures and markets integrated systems for genetic analysis, in particular next generation genomic sequencers which are used, among other things, in the development of cancer screening tests. Grail is an American biotechnology company which relies on genomic sequencing to develop such cancer screening tests. (...)